SRRK — Scholar Rock Holding Corporation stock price, charts and financials
QT69Scholar Rock Holding CorporationScholar Rock Holding Corporation (NASDAQ: SRRK) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -3.08 | Insider Own | 47.83% | Shs Outstand | 119.83M | Perf Week | 11.88% |
| Market Cap | 6.34B | Forward P/E | - | EPS next Y | -2.55 | Insider Trans | -0.21% | Shs Float | 96.39M | Perf Month | -8.66% |
| Enterprise Value | 6.11B | PEG | 1.46 | EPS next Q | - | Inst Own | - | Short Float | 18.26% | Perf Quarter | 13.93% |
| Income | -374.77M | P/S | 0.00 | EPS this Y | -3.36% | Inst Trans | - | Short Ratio | 12.20 | Perf Half Y | 19.06% |
| Sales | 47.00M | P/B | 27.24 | EPS next Y | 19.76% | ROA | -78.04% | Short Interest | 17.60M | Perf YTD | 20.14% |
| Book/sh | - | P/C | - | EPS next 5Y | - | ROE | -160.19% | 52W High | 56.60 -9.52% | Perf Year | 52.86% |
| Cash/sh | - | P/FCF | - | EPS past 3/5Y | - | ROIC | -88.80% | 52W Low | 26.20 95.49% | Perf 3Y | 622.95% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | - | Gross Margin | 0.00% | Volatility | 5.83% 4.83% | Perf 5Y | 69.34% |
| Dividend TTM | - | EV/Sales | 0.00 | EPS Y/Y TTM | -24.70% | Oper. Margin | 0.00% | ATR (14) | 2.53 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 7.02 | Sales Y/Y TTM | - | Profit Margin | 0.00% | RSI (14) | 57.61 | Recom | 2.00 |
| Dividend Gr. 3/5Y | - | Current Ratio | 7.02 | EPS Q/Q | -23.88% | SMA20 | 5.33% | Beta | 0.65 | Target Price | 61.83 |
| Payout | 0.00% | Debt/Eq | 0.80 | Sales Q/Q | - | SMA50 | 5.84% | Rel Volume | 0.70 | Prev Close | 52.92 |
| Employees | 289 | LT Debt/Eq | 0.42 | Earnings | Nov 13 | SMA200 | 17.15% | Avg Volume | 1.38M | Price | 51.21 |
| IPO Date | May 25, 2018 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -3.74% - | Net Debt/EBITDA | 0.59 | Volume | 958,143 | Change | -3.23% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-07-26 | Reiterated | BMO Capital | Outperform | $70 → $76 |
| May-08-26 | Reiterated | Barclays | Overweight | $53 → $55 |
| May-08-26 | Reiterated | HC Wainwright & Co. | Buy | $58 → $65 |
| Apr-20-26 | Initiated | Canaccord | Buy | $62 |
| Mar-04-26 | Reiterated | Piper Sandler | Overweight | $51 → $58 |
| Jan-26-26 | Reiterated | HC Wainwright & Co. | Buy | $58 |
| Jan-07-26 | Reiterated | UBS | $60 | |
| Dec-17-25 | Reiterated | Barclays | Overweight | $44 → $52 |
| Nov-14-25 | Reiterated | BMO Capital | Outperform | $45 → $50 |
| Sep-24-25 | Reiterated | Barclays | Overweight | $45 → $44 |
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 47 | 0 | 0 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 115 | 208 | 2 | — | — | — | — | — | — | |
| Gross Profit | -68 | -208 | -2 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 41 | 176 | 68 | — | — | — | — | — | — | |
| Research and Development | 115 | 208 | 183 | — | — | — | — | — | — | |
| Other Operating Expense | -115 | -208 | -1 | — | — | — | — | — | — | |
| Operating Income | -109 | -385 | -252 | — | — | — | — | — | — | |
| Interest Expense | 1 | 7 | 7 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -1 | 14 | 13 | — | — | — | — | — | — | |
| Net Income Before Taxes | -113 | -378 | -246 | — | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | — | — | — | — | — | — | |
| Consolidated Net Income | -113 | -378 | -246 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -113 | -378 | -246 | — | — | — | — | — | — | |
| Net Income | -113 | -378 | -246 | — | — | — | — | — | — | |
| EPS (Recurring) | -3.12 | -3.29 | -2.47 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -3.12 | -3.29 | -2.47 | — | — | — | — | — | — | |
| EPS (Diluted) | -3.08 | -3.29 | -2.47 | — | — | — | — | — | — | |
| EBITDA | -108 | -369 | -238 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 40.31 | — | — | — | — | — | — | — | — | |
| Gross Margin | -144.68 | — | — | — | — | — | — | — | — | |
| Operating Margin | -231.91 | — | — | — | — | — | — | — | — | |
| Net Margin | -240.43 | — | — | — | — | — | — | — | — | |
| Shares Outstanding | 37 | 115 | 100 | — | — | — | — | — | — | |
| Market Capitalization | 1,895 | 5,066 | 4,322 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| FLIER JEFFREY S. | Director | Jul 01 '26 | Sale | 53.88 | 3,053 | 164,490 | 27,856 | Jul 06 |
| Gilman Michael | Director | Jul 01 '26 | Sale | 53.88 | 2,544 | 137,058 | 59,511 | Jul 06 |
| Burow Kristina | Director | Jul 01 '26 | Sale | 53.74 | 3,053 | 164,064 | 114,657 | Jul 06 |
| Reed Joshua | Director | Jul 01 '26 | Sale | 53.74 | 3,053 | 164,068 | 19,518 | Jul 06 |
| Peng Katie | Director | Jul 01 '26 | Sale | 53.88 | 5,446 | 293,405 | 34,301 | Jul 06 |
| Burow Kristina | Director | Apr 23 '26 | Option Exercise | 9.13 | 89,800 | 820,324 | 110,871 | Apr 24 |
| Woods Keith | Chief Operating Officer | Apr 16 '26 | Sale | 49.57 | 10,220 | 506,651 | 620,055 | Apr 20 |
| Vaishnaw Akshay | President of R&D | Apr 16 '26 | Sale | 49.57 | 12,246 | 607,089 | 630,542 | Apr 20 |
| Sinha Vikas | Chief Financial Officer | Apr 16 '26 | Sale | 49.57 | 10,410 | 516,071 | 619,856 | Apr 20 |
| Hallal David | Chief Executive Officer | Apr 16 '26 | Sale | 49.57 | 30,615 | 1,517,723 | 1,639,034 | Apr 20 |
| Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Feb 23 '26 | Sale | 47.07 | 8,484 | 399,351 | 98,445 | Feb 25 |
| Marantz Jing L. | CHIEF MEDICAL OFFICER | Feb 17 '26 | Sale | 46.53 | 4,157 | 193,418 | 126,012 | Feb 19 |
| Ho Junlin | GENERAL COUNSEL | Feb 17 '26 | Sale | 46.53 | 9,580 | 445,740 | 241,545 | Feb 19 |
| Parlavecchio Caryn | CHRO | Feb 17 '26 | Sale | 46.53 | 9,035 | 420,382 | 169,087 | Feb 19 |
| Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Feb 17 '26 | Sale | 46.53 | 7,989 | 371,714 | 106,929 | Feb 19 |